Colorectal Cancer

The FDA approved nivolumab with ipilimumab in adult and pediatric patients with CRC based on data from the phase 3 CHECKMATE-8HW trial.

Muhammad Talha Waheed, MD, stated that a retrospective study found an OS benefit in CRC peritoneal metastasis with cytoreduction surgery without HIPEC vs with HIPEC.

Laparoscopic, histologic, and biomarker responses occurred at all dose levels of mitomycin treatment in patients with peritoneal metastases.

Sirexatamab plus bevacizumab/chemotherapy significantly improved overall response rate in patients with high DKK1 levels in the phase 2 DeFianCe study.

Antitumor efficacy end points favored placebo over trilaciclib prior to FOLFOXIRI/bevacizumab in patients with untreated metastatic colorectal cancer.

In a small cohort of patients with MMS/pMMR CRC, the suvemcitug and envafolimab pharmacokinetic profiles were comparable with prior monotherapy studies.

Phase 3 CheckMate-8HW trial results evaluating the combination in microsatellite instability–high or mismatch repair deficient CRC supported the decision.

Efficacy results demonstrated by regorafenib and sintilimab in patients with mSS mCRC were dependent on patient characteristics such location of metastasis and RAS type.

Adding panitumumab to sotorasib has yielded higher responses rates in KRAS G12C-mutated CRC compared with prior standards of care.

Full progression-free survival results for patients with BRAF V600E mCRC from the phase 3 BREAKWATER trial will be presented at an upcoming medical conference.

There were fewer adverse effects and no treatment-related deaths associated with thermal ablation vs surgical resection for patients with colorectal liver metastases.

Results from a phase 2 trial revealed serplulimab plus HLX04 elicited promising antitumor activity in patients with advanced hepatocellular carcinoma.

Additional progression-free survival data from the phase 3 BREAKWATER trial will be presented at future meetings.

The major pathologic response rate improved with extended time to surgery using botensilimab plus balstilimab in resectable colorectal cancer.

At a longer follow-up, adagrasib with cetuximab maintained meaningful efficacy and elicited an ORR of 34%, results from the phase 1/2 KRYSTAL-1 showed.

Phase 2 data may support fruquintinib plus TAS-102 as an alternative third-line treatment in patients with metastatic colorectal cancer.

The ALASCCA trial found that the risk of disease recurrence was reduced by 51% for patients with PIK3CA-mutated colorectal cancer who took aspirin for 3 years.

The BREAKWATER trial found that encorafenib and cetuximab with mFOLFOX6 chemotherapy generated an ORR of 60.9% in BRAF V600E–mutated metastatic colorectal cancer.

Post-operative ctDNA testing led to a change in adjuvant management in 1 of 6 patients with stage II/III colorectal cancer treated in the BESPOKE trial.

Updated results support nivolumab/ipilimumab as a standard of care in patients with MSI-H or dMMR metastatic colorectal cancer.

The results of a real-world study support palliative care integration in patients with advanced early-onset colorectal cancer.

No differences in oncologic outcomes occurred between mandatory TME or selective WW strategy in rectal cancer responders to neoadjuvant therapy.

Synchronous metastatic status does not appear to affect survival among patients with resected BRAF V600E-mutated metastatic colorectal cancer.

Trastuzumab/pertuzumab elicited similar efficacy and fewer high-grade AEs vs cetuximab/irinotecan in RAS/BRAF wild-type, HER2–positive metastatic CRC.

Results from the CodeBreaK 300 trial helped lead to the approval of sotorasib/panitumumab in KRAS G12C-mutated CRC.

Updated efficacy findings from the phase 3 CheckMate-8HW trial also showed fewer grade 3/4 adverse events with nivolumab/ipilimumab vs chemotherapy.

Nivolumab with ipilimumab elicited improvements to progression-free survival in patients with microsatellite instability–high colorectal cancer.

The FDA has granted accelerated approval to encorafenib in combination with cetuximab and mFOLFOX6 for patients with metastatic colorectal cancer with a BRAF V600E mutation, as detected by an FDA-approved test.

For patients with KRAS-mutated colorectal cancer, onvansertib plus FOLFIRI/bevacizumab was effective in those who had not received prior bevacizumab.

The CHMP recommended for approval nivolumab/ipilimumab for patients with MSI-H and dMMR unresectable or metastatic colorectal cancer.